Opaganib

Opaganib is a drug which acts as an inhibitor of the enzyme sphingosine kinase 2, dihydroceramide desaturase, and glucosylceramide synthase. It is under development as a potential treatment agent for several different kinds of cancer. Opaganib has also demonstrated antiviral activity against SARS-CoV-2 and has shown a reduction in mortality among patients with moderately severe COVID-19 in a multinational Phase 2/3 clinical trial and also appeared to exhibiting anti-inflammatory effects by reducing levels of IL-6 and TNF-alpha.